Volume | 47,885 |
|
|||||
News | - | ||||||
Day High | 5.9031 | Low High |
|||||
Day Low | 5.53 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
ESSA Pharma Inc | EPIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.84 | 5.53 | 5.9031 | 5.72 | 5.82 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
510 | 47,885 | $ 5.74 | $ 274,748 | - | 2.58 - 11.67 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 722 | $ 5.72 | USD |
ESSA Pharma Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
252.16M | 44.24M | - | 0 | -26.58M | -0.60 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
ESSA Pharma News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EPIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.75 | 6.82 | 5.53 | 6.02 | 44,334 | -1.03 | -15.26% |
1 Month | 6.22 | 6.85 | 5.5201 | 6.20 | 58,966 | -0.50 | -8.04% |
3 Months | 8.81 | 9.60 | 5.5201 | 7.13 | 59,225 | -3.09 | -35.07% |
6 Months | 5.13 | 11.67 | 4.92 | 8.40 | 108,408 | 0.59 | 11.50% |
1 Year | 3.02 | 11.67 | 2.58 | 6.21 | 109,408 | 2.70 | 89.40% |
3 Years | 31.87 | 32.81 | 1.40 | 6.01 | 482,856 | -26.15 | -82.05% |
5 Years | 2.30 | 36.00 | 1.40 | 7.62 | 335,459 | 3.42 | 148.70% |
ESSA Pharma Description
ESSA Pharma Inc is a pharmaceutical company. The company is in the preclinical stage, focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. |